Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Texas ulcer drug utilization review

Executive Summary

Program has saved $ 1.47 - $ 1.5 mil. in its first three months of operation, July through September. It requires pharmacists to contact physicians to suggest switching ulcer drug patients to maintenance level doses after two months of acute- level care, and covers all H[SUBSCRIPT]2 antagonist products such as Tagamet and Zantac and other ulcer therapies such as Prilosec and Carafate ("The Pink Sheet" Aug. 13, T&G-7). If savings continue near this rate, Texas says it could cut its ulcer drug spending by as much as 25%.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS018643

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel